JP2004536825A - 免疫疾患を治療する方法及び物質 - Google Patents
免疫疾患を治療する方法及び物質 Download PDFInfo
- Publication number
- JP2004536825A JP2004536825A JP2003506641A JP2003506641A JP2004536825A JP 2004536825 A JP2004536825 A JP 2004536825A JP 2003506641 A JP2003506641 A JP 2003506641A JP 2003506641 A JP2003506641 A JP 2003506641A JP 2004536825 A JP2004536825 A JP 2004536825A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- administering
- galectin
- modified pectin
- animal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 58
- 239000000126 substance Substances 0.000 title abstract description 35
- 208000026278 immune system disease Diseases 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 47
- 229920001277 pectin Polymers 0.000 claims abstract description 42
- 239000001814 pectin Substances 0.000 claims abstract description 42
- 235000010987 pectin Nutrition 0.000 claims abstract description 42
- 102000007563 Galectins Human genes 0.000 claims abstract description 34
- 108010046569 Galectins Proteins 0.000 claims abstract description 34
- 230000028993 immune response Effects 0.000 claims abstract description 14
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229930182830 galactose Natural products 0.000 claims abstract description 8
- 102000000802 Galectin 3 Human genes 0.000 claims abstract description 7
- 108010001517 Galectin 3 Proteins 0.000 claims abstract description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 7
- 102000000795 Galectin 1 Human genes 0.000 claims abstract description 6
- 108010001498 Galectin 1 Proteins 0.000 claims abstract description 6
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 6
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 4
- 108010038196 saccharide-binding proteins Proteins 0.000 claims abstract description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 229920002230 Pectic acid Polymers 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 5
- 239000010318 polygalacturonic acid Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229910052798 chalcogen Inorganic materials 0.000 claims description 2
- 150000001787 chalcogens Chemical class 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M thiocyanate group Chemical group [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 229920005615 natural polymer Polymers 0.000 abstract description 2
- 229920001059 synthetic polymer Polymers 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 13
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000000899 immune system response Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000031295 Animal disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- 229940040387 citrus pectin Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 229940100657 nasal ointment Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30036001P | 2001-06-22 | 2001-06-22 | |
| US10/176,022 US20030004132A1 (en) | 2001-06-22 | 2002-06-20 | Method and material for treating immune diseases |
| PCT/US2002/019886 WO2003000195A2 (en) | 2001-06-22 | 2002-06-21 | Method and material for treating immune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004536825A true JP2004536825A (ja) | 2004-12-09 |
| JP2004536825A5 JP2004536825A5 (https=) | 2006-01-05 |
Family
ID=26871794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003506641A Pending JP2004536825A (ja) | 2001-06-22 | 2002-06-21 | 免疫疾患を治療する方法及び物質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030004132A1 (https=) |
| EP (1) | EP1408989A2 (https=) |
| JP (1) | JP2004536825A (https=) |
| CN (1) | CN100558368C (https=) |
| BR (1) | BR0210547A (https=) |
| CA (1) | CA2451885A1 (https=) |
| IL (1) | IL159462A0 (https=) |
| WO (1) | WO2003000195A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
| DE602004014485D1 (de) | 2003-04-07 | 2008-07-31 | Prospect Therapeutics Inc | Zusammensetzung und anwendungen von galectin-antagonisten |
| US20050158321A1 (en) * | 2003-12-17 | 2005-07-21 | Entelos, Inc. | Treatment of rheumatoid arthritis with galectin-3 antagonists |
| WO2005095463A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
| US8728742B2 (en) * | 2011-03-17 | 2014-05-20 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
| MX363923B (es) | 2011-12-28 | 2019-04-08 | Galectin Therapeutics Inc | Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas. |
| CA2875979C (en) * | 2012-06-06 | 2021-01-26 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
| AU2013315019B2 (en) | 2012-09-17 | 2017-06-01 | Galectin Therapeutics, Inc. | Method for enhancing specific immunotherapies in cancer treatment |
| DK2906227T3 (en) | 2012-10-10 | 2018-12-10 | Galectin Therapeutics Inc | GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy |
| US12390486B2 (en) | 2012-12-20 | 2025-08-19 | Henry Ford Health System | Method for treating diastolic heart failure by inhibiting galectin-3 |
| JP2016507503A (ja) | 2012-12-20 | 2016-03-10 | ヘンリー フォード ヘルス システム | ガレクチン−３を阻害することによる拡張期心不全を治療する方法 |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
| CA3088736A1 (en) * | 2018-01-21 | 2019-07-25 | Rensselaer Polytechnic Institute | Method of treating galectin-3 dependent disorders |
| US20210138080A1 (en) | 2018-06-29 | 2021-05-13 | Glykos Biomedical Oy | Conjugates |
| WO2021123506A1 (en) | 2019-12-18 | 2021-06-24 | Glykos Biomedical Oy | Stabile conjugate |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5490991A (en) * | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
| AU638146B2 (en) * | 1990-06-27 | 1993-06-17 | Dainippon Ink And Chemicals Inc. | Alkylated oligosaccharides and acetyl derivatives of the same |
| US5498702A (en) * | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
| US5834442A (en) * | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
| US5831052A (en) * | 1997-05-07 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | New human translocation associated protein |
| US6258383B1 (en) * | 1998-08-14 | 2001-07-10 | Lactoferrin Products Company | Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format |
| US6500807B1 (en) * | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
-
2002
- 2002-06-20 US US10/176,022 patent/US20030004132A1/en not_active Abandoned
- 2002-06-21 JP JP2003506641A patent/JP2004536825A/ja active Pending
- 2002-06-21 IL IL15946202A patent/IL159462A0/xx unknown
- 2002-06-21 CN CNB028160916A patent/CN100558368C/zh not_active Expired - Fee Related
- 2002-06-21 EP EP02749642A patent/EP1408989A2/en not_active Withdrawn
- 2002-06-21 BR BR0210547-0A patent/BR0210547A/pt not_active IP Right Cessation
- 2002-06-21 CA CA002451885A patent/CA2451885A1/en not_active Abandoned
- 2002-06-21 WO PCT/US2002/019886 patent/WO2003000195A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003000195A2 (en) | 2003-01-03 |
| CA2451885A1 (en) | 2003-01-03 |
| CN100558368C (zh) | 2009-11-11 |
| US20030004132A1 (en) | 2003-01-02 |
| BR0210547A (pt) | 2004-05-25 |
| WO2003000195A3 (en) | 2003-03-20 |
| IL159462A0 (en) | 2004-06-01 |
| EP1408989A2 (en) | 2004-04-21 |
| CN1543352A (zh) | 2004-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004536825A (ja) | 免疫疾患を治療する方法及び物質 | |
| DE69231935T2 (de) | Konjugat enthaltend ein geradkettiges organisches polymer mit gebundenen sulfatierten glukosaminoglukanen wie zum beispiel heparin, seine herstellung, verwendung und ein entsprechendes substrat | |
| US9302013B2 (en) | Active principle for mitigating undesired medical conditions | |
| KR101831215B1 (ko) | 화장품 및 의약품 적용의 사용에 적합한 국소 투여된, 피부-침투성 글리코사미노글리칸 제형 | |
| SK459890A3 (en) | USE OF HYALURONIC ACID, THE SALTS THEREOF AND ANALOGUES FORì (54) PRODUCING A THERAPEUTIC AGENT TO TREAT DISEASES OR CONDIT | |
| US8754043B2 (en) | Epidermal growth factor compositions | |
| US9982027B2 (en) | Control of rheological properties of mixed hyaluronate/lubricin solutions | |
| US20070141101A1 (en) | Method for stimulating angiogenesis and wound healing | |
| CN109803977A (zh) | 核酸产品及其施用方法 | |
| JP2004535430A (ja) | 癌治療の有効性を向上させる方法 | |
| EP2178565A1 (fr) | COMPLEXES ENTRE UN POLYMÈRE AMPHIPHILE ET UNE PROTÉINE OSTÉOGÉNIQUE APPARTENANT À LA FAMILLE DES BMPs | |
| JP2001504493A (ja) | 糖尿病の症状を治療する方法 | |
| HU230385B1 (hu) | Részlegesen deszulfatált glükóz-amino-glükánok származékai mint a heparanáz enzim inhibitorai, előállításuk és alkalmazásuk, valamint ilyen származékokat tartalmazó gyógyszerkészítmények | |
| KR101464208B1 (ko) | 당뇨성 신경병증에서 말초 신경의 형태기능의 복원을 위한 상피 성장인자의 용도 | |
| CN102630157A (zh) | 组合了黏性补充剂和成纤维细胞生长培养基的关节内应用的可注射组合物 | |
| CN1794999B (zh) | 神经损伤治疗剂 | |
| JP2022088630A (ja) | 潤滑性ブロックコポリマーおよび生体模倣境界潤滑剤としてのそれらの使用 | |
| Chance et al. | Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: effects of glucagon-like peptide 2 | |
| KR20190070327A (ko) | 2가 아연 양이온을 갖는 히알루론산 겔 | |
| JP2004536825A5 (https=) | ||
| EP1561760A2 (en) | Low molecular weight heparin salt with thriethanolamine | |
| JP2021080271A (ja) | 転移を阻害し、線維症を処置し、かつ創傷の治癒を向上させる方法および組成物 | |
| JP2019528982A (ja) | 罹患椎間板の再生 | |
| AU2002320141A1 (en) | Method and material for treating immune diseases | |
| EP3570874B1 (en) | Zwitterionic polymer-insulin compositions and related methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050614 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050620 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080801 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081031 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081110 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081127 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081204 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090417 |